Literature DB >> 2564445

Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure.

B M Psaty1, T D Koepsell, J P LoGerfo, E H Wagner, T S Inui.   

Abstract

We conducted a population-based, case-control study to determine whether beta-blockers, used for the treatment of hypertension, prevent first events of coronary heart disease. Cases were patients who had high blood pressure treated with medicines and who presented in 1982 to 1984 with angina or fatal or nonfatal myocardial infarction. Controls were a probability sample of health maintenance organization patients with pharmacologically treated hypertension and free of coronary heart disease. Blinded to case-control status, we reviewed the medical records of the 248 cases and 737 controls. The health maintenance organization's computerized pharmacy database was used to ascertain the use of beta-blockers. Fewer cases than controls were taking beta-blockers. This difference was confined to those with nonfatal infarctions. After adjustment for confounding, the estimated relative risk was 0.62 (95% confidence interval, 0.39 to 0.99). Higher doses of beta-blockers conferred greater protection. We conclude that beta-blockers may prevent first events of nonfatal myocardial infarction in patients with high blood pressure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564445

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

1.  Adverse effects of observational studies when examining adverse outcomes of drugs: case-control studies with low prevalence of exposure.

Authors:  Peter C Austin; Muhammad Mamdani; Ivan J Williams
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Management of mild hypertension. Selecting an antihypertensive regimen.

Authors:  E J Pérez-Stable
Journal:  West J Med       Date:  1991-01

Review 3.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

4.  Diastolic blood pressure and the risk of primary cardiac arrest among pharmacologically treated hypertensive patients.

Authors:  D S Siscovick; T E Raghunathan; B M Psaty; T D Koepsell; L Cobb; P M Rautaharju; E H Wagner
Journal:  J Gen Intern Med       Date:  1996-06       Impact factor: 5.128

5.  Conducting comparative effectiveness research on medications: the views of a practicing epidemiologist from the other Washington.

Authors:  Bruce M Psaty
Journal:  Value Health       Date:  2011-11-09       Impact factor: 5.725

Review 6.  Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants.

Authors:  M J Kendall; I Rajman; S R Maxwell
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

7.  Record linkage as a research tool for office-based medical care.

Authors:  M M Finkelstein
Journal:  Can Fam Physician       Date:  1999-02       Impact factor: 3.275

8.  Atenolol quantification in human plasma by high-performance liquid chromatography: application to bioequivalence study.

Authors:  Luis Renato Pires de Abreu; Silvana Aparecida Calafatti de Castro; José Pedrazzoli
Journal:  AAPS PharmSci       Date:  2003

Review 9.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 10.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.